Lecanemab treatment group + Conventional anti-dementia treatment group
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Alzheimer's Disease
Conditions
Alzheimer's Disease, Lecanemab, Functional Magnetic Resonance Imaging
Trial Timeline
Mar 10, 2025 → Dec 31, 2026
NCT ID
NCT06871839About Lecanemab treatment group + Conventional anti-dementia treatment group
Lecanemab treatment group + Conventional anti-dementia treatment group is a pre-clinical stage product being developed by Eisai for Alzheimer's Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06871839. Target conditions include Alzheimer's Disease, Lecanemab, Functional Magnetic Resonance Imaging.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06871839 | Pre-clinical | Recruiting |
Competing Products
1 competing product in Alzheimer's Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VY7523 + Placebo Comparator | Voyager Therapeutics | Phase 1/2 | 33 |